Home | Welcome to Contract Pharma   
Last Updated Thursday, May 28 2015


Transgenomic, Raptor Enter Genetic Testing Services Pact

Published April 4, 2014
Related Searches: Testing Clinical Trial
Transgenomic, Inc. has entered an agreement with Raptor Pharmaceuticals, Inc. to provide genetic testing services for Raptor’s clinical trial evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. Leigh syndrome is a severe neurological disorder characterized by progressive loss of mental and movement abilities and typically results in death within a few years, usually due to respiratory failure.
“We look forward to working with Raptor and the study investigators, using our leading-edge mitochondrial genetic testing capabilities to uncover the important genetic profiling information required for the successful execution of this clinical trial,” said Paul Kinnon, president and chief executive officer of Transgenomic. “This is a key example of how Transgenomic works with pharmaceutical companies to employ complementary genetic tests designed to improve clinical diagnoses and outcomes.”

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On